HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124 May 27, 2025
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 13, 2025
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD)Â at AAI Annual Meeting May 5, 2025
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update March 12, 2025
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook January 14, 2025
